Stay updated with breaking news from Vstm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Verastem, Inc. (NASDAQ:VSTM – Get Free Report) has received an average rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in […]
BVF Inc. IL lowered its holdings in shares of Verastem, Inc. (NASDAQ:VSTM – Free Report) by 91.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,685,219 shares of the biopharmaceutical company’s stock after selling 17,337,437 shares during the period. BVF Inc. IL owned […]
Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in […]
Verastem (NASDAQ:VSTM – Get Free Report) and NextCure (NASDAQ:NXTC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation. Profitability This table compares Verastem and NextCure’s net margins, […]
Verastem (NASDAQ:VSTM – Free Report) had its price target reduced by Truist Financial from $39.00 to $34.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. A number of other analysts have also issued reports on the stock. B. Riley assumed coverage […]